ID   IMR-32rCARBO1000
AC   CVCL_ZX18
DR   Wikidata; Q102114224
RX   PubMed=31581737;
WW   Provider; RCCL; -; https://www.wass-michaelislab.org/rccl.php
CC   Part of: Resistant Cancer Cell Line (RCCL) collection.
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_31355; Carboplatin (CBP; Paraplatin).
CC   Derived from site: Metastatic; Abdomen; UBERON=UBERON_0000916.
ST   Source(s): PubMed=31581737
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 9
ST   D16S539: 8
ST   D18S51: 12,15
ST   D19S433: 14,15
ST   D21S11: 30,31
ST   D2S1338: 23,24
ST   D3S1358: 16
ST   D5S818: 11,12
ST   D7S820: 9,10
ST   D8S1179: 13
ST   FGA: 21,24
ST   Penta D: 11,12
ST   Penta E: 7,15
ST   TH01: 7,9.3
ST   TPOX: 11
ST   vWA: 15
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0346 ! IMR-32
SX   Male
AG   1Y1M
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 10-04-25; Version: 7
//
RX   PubMed=31581737; DOI=10.3390/cells8101194; PMCID=PMC6830094;
RA   Povey, Jane F.
RA   Saintas, Emily
RA   Aderemi, Adewale Victor
RA   Rothweiler, Florian
RA   Zehner, Richard
RA   Dirks, Wilhelm Gerhard
RA   Cinatl, Jindrich Jr.
RA   Racher, Andrew J.
RA   Wass, Mark N.
RA   Smales, Christopher Mark
RA   Michaelis, Martin
RT   "Intact-cell MALDI-ToF mass spectrometry for the authentication of
RT   drug-adapted cancer cell lines.";
RL   Cells 8:1194.1-1194.12(2019).
//